

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : <b>A61K 7/48, 7/06</b>	A1	(11) International Publication Number: <b>WO 97/17060</b> (43) International Publication Date: <b>15 May 1997 (15.05.97)</b>
(21) International Application Number: <b>PCT/US96/17672</b>		(81) Designated States: AU, CA, CN, CZ, JP, KR, MX, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
(22) International Filing Date: <b>5 November 1996 (05.11.96)</b>		
(30) Priority Data: <b>08/554,067 6 November 1995 (06.11.95) US</b>		<b>Published</b> <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(71) Applicant: <b>THE PROCTER &amp; GAMBLE COMPANY [US/US]; One Procter &amp; Gamble Plaza, Cincinnati, OH 45202 (US).</b>		
(72) Inventors: <b>BIEDERMANN, Kimberly, Ann; 20 Trailbridge, Cincinnati, OH 45241 (US). BISSETT, Donald, Lynn; 3925 Dust Commander Drive, Hamilton, OH 45011 (US). DECKNER, George, Endel; 10572 Tanager Hills Drive, Cincinnati, OH 45249 (US).</b>		
(74) Agents: <b>REED, T., David et al.; The Procter &amp; Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).</b>		

(54) Title: **TOPICAL COMPOSITIONS FOR REGULATING THE OILY/SHINY APPEARANCE OF SKIN**

(57) Abstract

Disclosed are topical compositions for regulating the oily and/or shiny appearance of skin. The compositions contain: (a) an active for regulating the oily and/or shiny appearance of skin, said active consisting essentially of one or more compounds selected from the group consisting of niacinamide, pyridoxine, panthenol, and pantothenic acid, in an amount that is safe and effective for regulating the oily and/or shiny appearance of the skin; and (b) a cosmetically acceptable carrier for said active. Also disclosed are methods of regulating the oily and/or shiny appearance of skin by topical application of such compositions.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LJ	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

## TOPICAL COMPOSITIONS FOR REGULATING THE OILY/SHINY APPEARANCE OF SKIN

5

Technical Field

The present invention relates to topical compositions, and especially topical compositions  
10 for facial and scalp application. The topical compositions are particularly useful for regulating the oily and/or shiny appearance of skin.

Background of the Invention

In the field of skin care compositions, the population is often classified by skin type, e.g.,  
dry, normal, oily, combined dry/normal, combined dry/oily, or combined normal/oily skin (the latter  
15 two classes hereinafter alternatively referred to as "combined skin").

Persons with an oily skin type or combined skin type typically manifest an oily and/or shiny  
skin appearance between cleansings. This oily or shiny appearance generally increases as the day  
progresses following cleansing of the skin. In order to avoid such appearance, individuals must  
throughout the day either cleanse the skin, blot the skin, apply oil absorbing powders to the skin, or  
20 take some other measure to minimize the appearance of oil or shine.

Therefore, it has been desired in the art to provide topical compositions which minimize  
the appearance of oil and/or shine on the skin, especially oily or combined skin. Several topical  
compositions which are said to be designed for controlling oily and/or shiny skin are known in the  
art. For example, facial moisturizers and make-up said to have such property are known.

25 An oily or combined skin type presents a particular challenge to the formulation of make-up  
intended for facial use, including foundations. This is because as oil accumulates on the facial  
skin of such individuals, oil breakthrough occurs (the oil is not masked by the make-up such that an  
oily or shiny skin appearance results), and the coverage and wear resistance of the make-up tends to  
be reduced. It would be desirable to provide a make-up that maintains a high degree of coverage  
30 and wear resistance after application to all skin types, including oily and combined skin, preferably  
substantially as originally applied.

While certain formulations have been designed in an attempt to control the oily and/or  
shiny appearance of skin, there remains a need to provide improved topical compositions for  
minimizing the appearance of skin oil and/or shine. In addition to minimizing oil and/or shine,  
35 such compositions should not unacceptably discolor the skin. There is a particular need to provide  
improved facial make-up which minimizes the appearance of skin oil and/or shine, provides and  
maintains an even (i.e., uniform coverage) complexion and acceptable skin tone for extended

periods after application, and/or which has extended wear resistance after application.

The B vitamins or vitamin B complex have heretofore been used to treat a number of conditions. For example, the following compounds have had the respective applications: riboflavin (acne, diabetes, anti-oxidant therapy, anemia, skin disorders, stress); nicotinic acid (atherosclerosis, 5 pellegra, high cholesterol, high blood pressure, skin inflammation, antioxidant therapy); nicotinamide (pellagra, skin inflammation, anti-oxidant therapy); pantothenic acid (acne, anemia, arthritis, high cholesterol, atherosclerosis, alcohol detoxification, infections, hair loss); pyridoxine (acne, anemia, high cholesterol, skin inflammation, immune disorders, antioxidant therapy, carpal tunnel syndrome, premenstrual syndrome). These utilities and those of other B vitamin (complex) 10 compounds are further described, along with a discussion of their contraindications and deficiency symptoms, in The Doctor's Vitamin and Mineral Encyclopedia, Hender, S.S., pp. 49-82 (Simon & Schuster, New York 1990) and Nutrients Catalog, Newstrom, H., pp. 11-90 (McFarland & Co. 1993).

It has now been found that certain B vitamins are useful when topically applied for 15 regulating the appearance of oily and/or shiny skin, including oily and combined skin, without unacceptably discoloring the skin, e.g., by unacceptable skin flushing or reddening. It has surprisingly been found that topical compositions containing these compounds in the form of a facial make-up composition minimize the appearance of skin oil and/or shine, provide and maintain substantially uniform coverage and an acceptable skin tone for extended periods after application, 20 and/or have extended wear resistance after application.

It is an object of the present invention to provide topical compositions for regulating the oily and/or shiny appearance of mammalian skin, especially facial skin. It is a further object of this invention to provide such topical compositions which regulate the appearance of oily and/or shiny mammalian skin, provide and maintain substantially uniform coverage for extended periods after 25 application to the skin, provide and maintain an acceptable skin tone for extended periods after application to the skin, and/or have extended wear resistance after application to the skin. Another object of the present invention is to provide methods of regulating the appearance of oily and/or shiny mammalian skin.

Other objects of the subject invention will be apparent from the disclosure which follows.

30 Summary of the Invention

The present invention relates to topical compositions for regulating the oily and/or shiny appearance of mammalian skin, and especially facial skin. The compositions comprise a suitable active in an amount that is safe and effective for regulating the oily and/or shiny appearance of the skin, and a cosmetically acceptable topical carrier for the active. Preferred actives are those which 35 effectively regulate the oily and/or shiny appearance of skin, and which do not unacceptably discolor the skin, e.g., unacceptably cause reddening or flushing of the skin. Suitable actives include those selected from the group consisting of niacinamide, pyridoxine, panthenol, pantothenic acid and

mixtures thereof (these actives are alternatively referred to herein, individually or collectively, as "primary actives"). It has surprisingly been found that such actives, when topically applied to the skin, are especially useful for regulating the appearance of oily and/or shiny skin, including oily and combined skin, without unacceptably discoloring the skin, e.g., by unacceptable skin flushing or reddening. It has surprisingly been found that topical compositions containing these compounds in the form of a facial make-up composition minimize the appearance of skin oil and/or shine, provide and maintain substantially uniform coverage and acceptable skin tone for extended periods after application, and/or have extended wear resistance after application.

In preferred embodiments, the primary active comprises niacinamide. More preferably, the primary active consists essentially of niacinamide. Where niacinamide is used, it is preferably substantially pure niacinamide. The primary active is preferably used in an amount of from about 2.5% to about 5% by weight of the composition.

The present invention also relates to methods of regulating the oily and/or shiny appearance of mammalian skin by topical application of such compositions.

**15 Detailed Description of Preferred Embodiments**

The compositions of the present invention are useful as topical compositions, i.e., they are suitable for topical administration to a biological subject such as a mammal. As used herein, "topical" means applied to the surface of the skin. The compositions of the subject invention are administered topically to a biological subject, i.e., by the direct laying on or spreading of the composition on the skin of the subject.

The topical compositions comprise a safe and effective amount of one or more primary actives and a cosmetically acceptable topical carrier for the primary actives.

As used herein "comprising" means that other steps and ingredients which do not affect the end result can be added. This term encompasses the terms "consisting of" and "consisting essentially of". The phrase "consisting essentially of" means that the composition may include additional ingredients, but only if the additional ingredients do not materially alter the basic and novel characteristics of the claimed compositions or methods.

As used herein, "safe and effective amount" means a sufficient amount of a compound, composition or other material described by this phrase to significantly induce a positive modification in the condition being treated, but low enough to avoid significant side effects (e.g., significant skin irritation or sensitization), within the scope of sound judgment of the skilled artisan. The safe and effective amount of the compound, composition or other material may vary with the particular skin being treated, the age and physical condition of the biological subject being treated, the severity of the condition, the duration of the treatment, the nature of concurrent therapy, the specific compound, composition or other material employed, the particular cosmetically acceptable topical carrier utilized, and like factors within the knowledge and expertise of the skilled artisan.

As used herein, "cosmetically acceptable" means that a material (e.g., compound or

composition) which the phrase describes is suitable for use in contact with the tissues of humans and lower animals without undue toxicity, incompatibility, instability, irritation, allergic response and the like.

As used herein, "regulating the oily and/or shiny appearance of skin" means preventing, 5 retarding and/or arresting the appearance of oil and/or shine on the skin. By regulating the oily and/or shiny appearance of the skin, one or more of the following benefits are achieved: there is a noticeable decrease in the visible oil, shine, or highlights on the skin; the skin is substantially free from visible oiliness, shine, or highlights; the skin has a substantially matte finish; the user has a more uniform complexion. Regulating the oily and/or shiny appearance of the skin may result in 10 more uniform and lasting coverage of the skin by the composition, increased wear resistance of the composition and/or a decrease in the incidence or severity of skin oil breaking through the composition so as to become visibly apparent.

Unless otherwise stated, all percentages herein are weight percentages based on the weight of the composition.

15 As used herein, "mixtures" is meant to include a simple combination of materials and any compounds that may result from their combination.

#### Primary Actives

The compositions of this invention comprise one or more suitable primary actives in an amount that is safe and effective for regulating the oily and/or shiny appearance of the skin. 20 Suitable actives are those which effectively regulate the oily and/or shiny appearance of skin without unacceptably discoloring the skin, e.g., unacceptably causing reddening or flushing of the skin.

Compounds that possess significant vasodilatory properties are typically unsuitable for use 25 as a primary active. Such vasodilatory compounds tend to cause unacceptable flushing or reddening of the skin such that their use, especially in facial applications, is not desirable. For example, known vasodilators such as nicotinic acid are not suitable for use herein.

Preferred compositions of this invention comprise as primary actives one or more compounds selected from the group consisting of niacinamide, pyridoxine, panthenol, pantothenic acid, and mixtures thereof. In a preferred embodiment, the primary actives are substantially pure. By substantially pure it is meant that the compound described by that phase is at least 90% pure, at 30 least more preferably 95% pure, most preferably 99% pure.

In a preferred embodiment, the primary active comprises niacinamide, which is more preferably substantially pure niacinamide. Thus, the primary active may consist essentially of:

- (a) niacinamide; or
- (b) a mixture of (i) niacinamide and (ii) a compound selected from the group 35 consisting of panthenol, pantothenic acid, and pyridoxine.

Preferably, the composition comprises from about 0.01% to about 20%, by weight, of primary active, more preferably from about 0.1% to about 10%, by weight, of primary active, even

more preferably from about 1% to about 5%, by weight, of primary active, most preferably from about 2.5% to about 5%, by weight, of primary active, also from about 3% to about 5% primary active.

In an especially preferred embodiment, the topical composition comprises from about 2.5%

5 to about 5%, by weight, of niacinamide, which is preferably substantially pure niacinamide.

#### Cosmetically Acceptable Carrier

The phrase "cosmetically acceptable carrier", as used herein, means one or more compatible solid or liquid fillers, diluents, extenders and the like, which are cosmetically acceptable as defined herein. The term "compatible", as used herein, means that the components of the compositions of 10 this invention are capable of being commingled with the primary actives of the present invention, and with each other, in a manner such that there is no interaction which would substantially reduce the efficacy of the composition under ordinary use situations.

The type of carrier utilized in the present invention depends on the type of product desired. 15 The topical compositions useful in the subject invention may be made into a wide variety of product types. These include, but are not limited to, lotions, creams, gels, sticks, sprays, ointments, pastes, mousses and cosmetics (e.g., solid, semi-solid, or liquid make-up, including foundations). These product types may comprise several types of carriers including, but not limited to, solutions, aerosols, emulsions (including oil-in-water or water-in-oil), gels, solids, and liposomes.

Solutions according to the subject invention typically include a cosmetically acceptable 20 aqueous or organic solvent which is capable of having the primary active dispersed or dissolved therein. Water is a preferred solvent. Examples of suitable organic solvents include: propylene glycol, polyethylene glycol (e.g., Molecular Weight 200-600 g/mole), polypropylene glycol (e.g., Molecular Weight 425-2025 g/mole), glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, isopropanol, sorbitol esters, butanediol, and mixtures thereof. Solutions useful in the 25 subject invention preferably contain from about 80% to about 99.99% of the aqueous or organic solvent and primary active in the above described amounts.

Aerosols according to the subject invention can be formed by adding a propellant to a solution such as described above. Exemplary propellants include chloro-fluorinated lower 30 molecular weight hydrocarbons. Additional propellants that are useful herein are described in Sagarin, Cosmetics Science and Technology, 2nd Edition, Vol. 2, pp. 443-465 (1972), incorporated herein by reference. Aerosols are typically applied to the skin as a spray-on product.

Emulsions according to the present invention generally contain a solution as described above and a lipid or oil. Lipids and oils may be derived from animals, plants, or petroleum and may be natural or synthetic (i.e., man-made). Preferred emulsions also contain a humectant, such as 35 glycerin. Emulsions will preferably further contain from about 1% to about 10%, more preferably from about 2% to about 5%, of an emulsifier, based on the weight of the carrier. Emulsifiers may be nonionic, anionic or cationic. Suitable emulsifiers are disclosed in, for example, U.S. Patent

3,755,560, issued August 28, 1973, Dickert et al.; U.S. Patent 4,421,769, issued December 20, 1983, Dixon et al.; and McCullough's Detergents and Emulsifiers, North American Edition, pages 317-324 (1986), each incorporated herein by reference.

The emulsion may also contain an anti-foaming agent to minimize foaming upon application to the skin. Anti-foaming agents include high molecular weight silicones and other materials well known in the art for such use.

Preferred emulsions have a low viscosity, of about 50 centistokes or less, more preferably about 10 centistokes or less, most preferably about 5 centistokes or less.

The topical compositions of the subject invention may comprise a topical cosmetically acceptable emollient. Such compositions preferably contain from about 2% to about 50% of the emollient. As used herein, "emollient" refers to a material used for the prevention or relief of dryness, as well as for the protection of the skin. A wide variety of suitable emollients are known and may be used herein. Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 32-43 (1972), incorporated herein by reference, contains numerous examples of materials suitable as an emollient.

Lotions and creams according to the present invention generally comprise a solution carrier system and one or more emollients. Lotions typically comprise from about 1% to about 20%, preferably from about 5% to about 10% of emollient; from about 50% to about 90%, preferably from about 60% to about 80%, water; and primary active in the above described amounts. A cream typically comprises from about 5% to about 50%, preferably from about 10% to about 20% of emollient; from about 45% to about 85%, preferably from about 50% to about 75%, water; and primary active in the above described amounts.

In addition to the primary active, ointments of the present invention may comprise a simple carrier base of animal or vegetable oils or semi-solid hydrocarbons (oleaginous); absorption ointment bases which absorb water to form emulsions; or water soluble carriers, e.g., a water soluble solution carrier. Ointments may further comprise a thickening agent, such as described in Sagarin, Cosmetics, Science and Technology, 2nd Edition, Vol. 1, pp. 72-73 (1972), incorporated herein by reference, and/or an emollient. For example, an ointment may comprise from about 2% to about 10% of an emollient; from about 0.1% to about 2% of a thickening agent; and primary active in the above described amount.

Compositions of this invention useful for cleansing ("cleansers") are formulated with a suitable carrier, e.g., as described above, and preferably contain, in addition to the primary active in the above described amounts, from about 1% to about 90%, more preferably from about 5% to about 10% of a cosmetically acceptable surfactant. The surfactant is suitably selected from anionic, nonionic, zwitterionic, amphoteric and ampholytic surfactants, as well as mixtures of these surfactants. Such surfactants are well known to those skilled in the detergency art. Nonlimiting examples of possible surfactants include isoocteth-20, sodium methyl cocoyl taurate, sodium methyl

oleoyl taurate, and sodium lauryl sulfate. See U.S. Patent No. 4,800,197, to Kowcz et al., issued January 24, 1989, which is incorporated herein by reference in its entirety, for exemplary surfactants useful herein. Examples of a broad variety of additional surfactants useful herein are described in McCutcheon's Detergents and Emulsifiers, North American Edition (1986), published by Allured Publishing Corporation, which is incorporated herein by reference in its entirety. The cleansing compositions can optionally contain, at their art-established levels, other materials which are conventionally used in cleansing compositions.

The physical form of the cleansing compositions is not critical. The compositions can be, for example, formulated as toilet bars, liquids, shampoos, bath gels, hair conditioners, hair tonics, pastes, or mousses. Toilet bars are most preferred since this is the form of cleansing agent most commonly used to wash the skin. Rinse-off cleansing compositions, such as shampoos, require a delivery system adequate to deposit sufficient levels of actives on the skin and scalp. A preferred delivery system involves the use of insoluble complexes. For a more complete disclosure of such delivery systems, see U.S. Patent 4,835,148, Barford et al., issued May 30, 1989, incorporated herein by reference in its entirety.

As used herein, the term "foundation" refers to a liquid, semi-liquid, semi-solid, or solid skin cosmetic which includes, but is not limited to lotions, creams, gels, pastes, cakes, and the like. Typically the foundation is used over a large area of the skin, such as over the face, to provide a particular look. Foundations are typically used to provide an adherent base for color cosmetics such as rouge, blusher, powder and the like, and tend to hide skin imperfections and impart a smooth, even appearance to the skin. Foundations of the present invention include a cosmetically acceptable carrier for the primary active and may include conventional ingredients such as oils, colorants, pigments, emollients, fragrances, waxes, stabilizers, and the like. Exemplary carriers and such other ingredients which are suitable for use herein are described, for example, in copending patent application Serial No. 08/430,961, filed on April 28, 1995 in the names of Marcia L. Canter, Brian D. Barford, and Brian D. Hofrichter, incorporated herein by reference.

The compositions of the present invention are preferably formulated to have a pH of 8 or below. The pH values of these compositions preferably range from about 2 to about 8, more preferably from about 3 to about 6, most preferably from about 4.5 to about 5.5.

30

#### Optional Ingredients

The compositions of this invention may contain other ingredients conventionally used in the art of skin care compositions, including but not limited to preservatives, preservative enhancers, and actives in addition to the primary actives. Any optional ingredients should be compatible with the primary active such that the activity of the primary active does not decrease unacceptably, preferably not to any significant extent, over a useful period (preferably at least about two years under normal storage conditions). For example, strong oxidizing agents may be incompatible with the primary active such that such agents are preferably avoided.

Other Actives

The compositions of the subject invention may optionally comprise other actives capable of functioning in different ways to enhance the benefits of the primary actives and/or to provide other benefits. Examples of such substances include, but are not limited to, anti-inflammatory agents.

5 antimicrobial agents, anti-androgens, sunscreens, sunblocks, anti-oxidants/radical scavengers, chelators, depilation agents, desquamation agents, organic hydroxy acids, and natural extracts.

A. Anti-Inflammatory Agents

A safe and effective amount of an anti-inflammatory agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 0.5% 10 to about 5% of the composition. The anti-inflammatory agent enhances the skin appearance benefits of the present invention, e.g., such agents contribute to a more uniform and acceptable skin tone. The exact amount of anti-inflammatory agent to be used in the compositions will depend on the particular anti-inflammatory agent utilized since such agents vary widely in potency.

Steroidal anti-inflammatory agents, including but not limited to, corticosteroids such as 15 hydrocortisone, hydroxyltriamcinolone, alpha-methyl dexamethasone, dexamethasone-phosphate, beclomethasone dipropionate, clobetasol valerate, desonide, desoxymethasone, desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasone diacetate, diflucortolone valerate, fludrenolone, fluclorolone acetonide, fludrocortisone, flumethasone pivalate, fluosinolone acetonide, fluocinonide, flucortine butyesters, flucortolone, fluprednidene (fluprednylidene) acetate, flurandrenolone, halcinonide, hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone, triamcinolone acetonide, cortisone, cortodoxone, flucetonide, fludrocortisone, difluorosone diacetate, fluradrenolone, fludrocortisone, difluorosone diacetate, fluradrenolone acetonide, medrysone, amcinafel, amcinafide, betamethasone and the balance of its esters, chloroprednisone, chlorprednisone acetate, clocortolone, clescinolone, dichlorisone, diflurprednate, 25 flucloronide, flunisolide, fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate, hydrocortisone cyclopentylpropionate, hydrocortamate, meprednisone, paramethasone, prednisolone, prednisone, beclomethasone dipropionate, triamcinolone, and mixtures thereof may be used. The preferred steroid anti-inflammatory for use is hydrocortisone.

A second class of anti-inflammatory agents which is useful in the compositions includes the 30 nonsteroidal anti-inflammatory agents. The variety of compounds encompassed by this group are well-known to those skilled in the art. For detailed disclosure of the chemical structure, synthesis, side effects, etc. of non-steroidal anti-inflammatory agents, reference may be had to standard texts, including Anti-inflammatory and Anti-Rheumatic Drugs, K.D. Rainsford, Vol. I-III, CRC Press, Boca Raton, (1985), and Anti-inflammatory Agents, Chemistry and Pharmacology, I. R.A. Scherrer, et al., Academic Press, New York (1974), each incorporated herein by reference.

Specific non-steroidal anti-inflammatory agents useful in the composition invention include, but are not limited to:

- 1) the oxycams, such as piroxicam, isoxicam, tenoxicam, sudoxicam, and CP-14,304;
- 2) the salicylates, such as aspirin, disalcid, benorylate, trilisate, safaprin, solprin, diflunisal, and fendosal;
- 3) the acetic acid derivatives, such as diclofenac, fenclufenac, indometacin, sulindac, tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin, fentiazac, zomepirac, clindanac, oxepinac, felbinac, and ketorolac;
- 4) the fenamates, such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamic acids;
- 5) the propionic acid derivatives, such as ibuprofen, naproxen, benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen, indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miprofen, tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and
- 10 6) the pyrazoles, such as phenylbutazone, oxyphenbutazone, seprazole, azapropazone, and trimethazone.

15 Mixtures of these non-steroidal anti-inflammatory agents may also be employed, as well as the cosmetically acceptable salts and esters of these agents. For example, etofenamate, a flufenamic acid derivative, is particularly useful for topical application. Of the nonsteroidal anti-inflammatory agents, ibuprofen, naproxen, flufenamic acid, mefenamic acid, meclofenamic acid, piroxicam and felbinac are preferred; ibuprofen, naproxen, and flufenamic acid are most preferred.

20 Finally, so-called "natural" anti-inflammatory agents are useful in methods of the subject invention. For example, candelilla wax, alpha bisabolol, aloe vera, Manjistha (extracted from plants in the genus *Rubia*, particularly *Rubia Cordifolia*), and Guggal (extracted from plants in the genus *Commiphora*, particularly *Commiphora Mukul*), may be used.

25 **B. Retinoids**

30 A safe and effective amount of a retinoid may be added to the compositions of the subject invention, preferably from about 0.001% to about 0.5%, more preferably from about 0.01% to about 0.1% of the composition. As used herein, "retinoid" includes all natural and/or synthetic analogs of Vitamin A or retinol-like compounds which possess the biological activity of Vitamin A in the skin as well as the geometric isomers and stereoisomers of these compounds, such as all-trans retinoic acid and 13-cis-retinoic acid. The retinoid is preferably retinol, retinal, or retinoic acid, more preferably retinoic acid.

35 The retinoids enhance the skin appearance benefits of the present invention. For example, the retinoids may diminish fine lines, wrinkles, or other textural discontinuities. Such benefits are themselves desirable and in the present invention, tend to also improve application of the present compositions.

35 **C. Antimicrobial Agents**

As used herein, "antimicrobial agent" means a compound capable of destroying microbes.

preventing the development of microbes or preventing the pathogenic action of microbes. Antimicrobial agents are useful, for example, in controlling acne. A safe and effective amount of an antimicrobial agent may be added to compositions of the subject invention, preferably from about 0.001% to about 10%, more preferably from about 0.01% to about 5%, also from about 0.05% to 5 about 2% or from about 0.05% to about 1% of the compositions. Preferred antimicrobial agents useful in the subject invention are benzoyl peroxide, erythromycin, tetracycline, clindamycin, azelaic acid, and sulfur resorcinol.

**D. Antiandrogens**

As used herein, "anti-androgen" means a compound capable of correcting androgen-related 10 disorders by interfering with the action of androgens at their target organs. The target organ for the subject invention is mammalian skin.

**E. Sunscreens and Sunblocks**

Exposure to ultraviolet light can result in excessive scaling and texture changes of the stratum corneum. Therefore, the compositions of the subject invention preferably contain a 15 sunscreen or sunblock. Suitable sunscreens or sunblocks may be organic or inorganic.

A wide variety of conventional sunscreening agents are suitable for use herein. Sagarin, et al., at Chapter VIII, pages 189 et seq., of Cosmetics Science and Technology (1972), discloses numerous suitable agents, and is incorporated herein by reference. Specific suitable sunscreening agents include, for example: p-aminobenzoic acid, its salts and its derivatives (ethyl, isobutyl, 20 glyceryl esters; p-dimethylaminobenzoic acid); anthranilates (i.e., o-amino-benzoates; methyl, menthyl, phenyl, benzyl, phenylethyl, linalyl, terpinyl, and cyclohexenyl esters); salicylates (amyl, phenyl, octyl, benzyl, menthyl, glycetyl, and di-pro-pylene glycol esters); cinnamic acid derivatives (menthyl and benzyl esters,  $\alpha$ -phenyl cinnamonnitrile; butyl cinnamoyl pyruvate); dihydroxycinnamic acid derivatives (umbelliferone, methylumbelliferone, methylacet-o-umbelliferone); trihydroxy- 25 cinnamic acid derivatives (esculetin, methylesculetin, daphnetin, and the glucosides, esculin and daphnin); hydrocarbons (diphenylbutadiene, stilbene); dibenzalacetone and benzalacetophenone; naphtholsulfonates (sodium salts of 2-naphthol-3,6-disulfonic and of 2-naphthol-6,8-disulfonic acids); di-hydroxynaphthoic acid and its salts; o- and p-hydroxybiphenyl disulfonates; coumarin derivatives (7-hydroxy, 7-methyl, 3-phenyl); diazoles (2-acetyl-3-bromoindazole, phenyl 30 benzoxazole, methyl naphthoxazole, various aryl benzothiazoles); quinine salts (bisulfate, sulfate, chloride, oleate, and tannate); quinoline derivatives (8-hydroxyquinoline salts, 2-phenylquinoline), hydroxy- or methoxy-substituted benzophenones; uric and violuric acids; tannic acid and its derivatives (e.g., hexaethyl ether); (butyl carbotol) (6-propyl piperonyl) ether; hydroquinone, benzophenones (oxybenzene, sulisobenzene, dioxybenzene, benzoresorcinol, 2,2'-4,4'- 35 tetrahydroxybenzophenone, 2,2'-dihydroxy-4,4'-dimethoxybenzophenone, octabenzene; 4-isopropylidibenzoylmethane; butylmethoxydibenzoylmethane; citrocrylic;  $\beta$ -(4'-methylbenzylidene bornan-2-one) and 4-isopropyl-di-benzoylmethane.

Of these, 2-ethylhexyl-p-methoxycinnamate, 4,4'-*t*-butyl methoxydibenzoyl-methane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid, digalloyltriolate, 2,2-dihydroxy-4-methoxybenzophenone, ethyl-4-(bis(hydroxy-propyl))aminobenzoate, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, 2-ethylhexyl-salicylate, glyceryl-p-aminobenzoate, 3,3,5-trimethylcyclohexylsalicylate, methylanthranilate, p-dimethyl-aminobenzoic acid or aminobenzoate, 2-ethylhexyl-p-dimethyl-amino-benzoate, 2-phenylbenzimidazole-5-sulfonic acid, 2-(p-dimethylaminophenyl)-5-sulfonicbenzoxazolic acid and mixtures of these compounds, are preferred.

More preferred sunscreens useful in the compositions useful in the subject invention are 2-ethylhexyl-p-methoxycinnamate, butylmethoxydibenzoylmethane, 2-hydroxy-4-methoxybenzophenone, octyldimethyl-p-aminobenzoic acid and mixtures thereof.

Also particularly useful in the compositions are sunscreens such as those disclosed in U.S. Patent No. 4,937,370 issued to Sabatelli on June 26, 1990, and U.S. Patent No. 4,999,186 issued to Sabatelli & Spirnak on March 12, 1991, both of which are incorporated herein by reference. The sunscreening agents disclosed therein have, in a single molecule, two distinct chromophore moieties which exhibit different ultra-violet radiation absorption spectra. One of the chromophore moieties absorbs predominantly in the UVB radiation range and the other absorbs strongly in the UVA radiation range.

Preferred members of this class of sunscreening agents are 4-N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester of 2,4-dihydroxybenzophenone; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester with 4-hydroxydibenzoylmethane; 4-N,N-(2-ethylhexyl)methyl-aminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; 4-N,N-(2-ethylhexyl)-methylaminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane; N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 2-hydroxy-4-(2-hydroxyethoxy)benzophenone; and N,N-di-(2-ethylhexyl)-4-aminobenzoic acid ester of 4-(2-hydroxyethoxy)dibenzoylmethane and mixtures thereof.

Suitable inorganic sunscreens or sunblocks include metal oxides, e.g., zinc oxide and titanium dioxide. For example, the use of a titanium dioxide in topical sunscreen compositions that is applicable to the present invention is described in copending application Serial No. 08/448,942, filed on May 24, 1995, in the names of Jiang Yue, Lisa R. Dew and Donald L. Bissett, incorporated herein by reference.

A safe and effective amount of the sunscreen or sunblock is used, typically from about 1% to about 20%, more typically from about 2% to about 10%. Exact amounts will vary depending upon the sunscreen chosen and the desired Sun Protection Factor (SPF).

An agent may also be added to any of the compositions useful in the subject invention to improve the skin substantivity of those compositions, particularly to enhance their resistance to being washed off by water, or rubbed off. A preferred agent which will provide this benefit is a copolymer of ethylene and acrylic acid. Compositions comprising this copolymer are disclosed in

U.S. Patent 4,663,157, Brock, issued May 5, 1987, which is incorporated herein by reference

**F. Anti-Oxidants/Radical Scavengers**

Preferred compositions of the subject invention include an anti-oxidant/radical scavenger as an active in addition to the primary active agents. The anti-oxidant/radical scavenger provides 5 protection against UV radiation which can cause increased scaling or texture changes in the stratum corneum and against other environmental agents which can cause skin damage

A safe and effective amount of an anti-oxidant/radical scavenger may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5% of the composition.

10 Anti-oxidants/radical scavengers such as ascorbic acid (vitamin C) and its salts, tocopherol (vitamin E), tocopherol sorbate, other esters of tocopherol, butylated hydroxy benzoic acids and their salts, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (commercially available under the trademark Trolox<sup>R</sup>), gallic acid and its alkyl esters, especially propyl gallate, uric acid and its salts and alkyl esters, sorbic acid and its salts, the ascorbyl esters of fatty acids, amines (e.g., N,N-15 diethylhydroxylamine, amino-guanidine), sulphydryl compounds (e.g., glutathione) and dihydroxy fumaric acid and its salts may be used. Preferred anti-oxidants/radical scavengers are selected from tocopherol sorbate and other esters of tocopherol. For example, the use of tocopherol sorbate in topical compositions and applicable to the present invention is described in U.S. Patent No. 4,847,071, issued on July 11, 1989 to Donald L. Bissett, Rodney D. Bush and Ranjit Chatterjee.

20 incorporated herein by reference.

**G. Chelators**

As used herein, "chelating agent" means an active agent capable of removing a metal ion from a system by forming a complex so that the metal ion cannot readily participate in or catalyze 25 chemical reactions. The inclusion of a chelating agent provides protection against UV radiation which can contribute to excessive scaling or skin texture changes and against other environmental agents which can cause skin damage.

A safe and effective amount of a chelating agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 1% to about 5% of the composition. Exemplary chelators that are useful herein are disclosed in U.S. Patent Application Serial No. 619,805, Bissett, Bush & Chatterjee, filed November 27, 1990 (which is a continuation of U.S. Patent Application Serial No. 251,910, filed October 4, 1988); U.S. Patent Application Serial No. 514,892, Bush & Bissett, filed April 26, 1990; and U.S. Patent Application Serial No. 657,847, Bush, Bissett & Chatterjee, filed February 25, 1991; all incorporated herein by reference. Preferred chelators useful in compositions of the subject invention are furildioxime and 35 derivatives thereof.

**H. Organic Hydroxy Acids**

The compositions of the present invention preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2%, of an organic hydroxy acid such as salicylic acid, glycolic acid, or lactic acid. Salicylic acid is 5 preferred. The organic hydroxy acids enhance the skin appearance benefits of the present invention. For example, the organic hydroxy acids tend to improve the texture of the skin.

**J. Desquamation Agents**

A safe and effective amount of a desquamation agent may be added to the compositions of the subject invention, preferably from about 0.1% to about 10%, more preferably from about 0.2% to 10 about 5%, also preferably from about 0.5% to about 4% of the composition. Desquamation agents enhance the skin appearance benefits of the present invention. For example, the desquamation agents tend to improve the texture of the skin (e.g., smoothness). A variety of desquamation agents are known in the art and are suitable for use herein, including but not limited to the organic hydroxy agents described above. One desquamation system that is suitable for use herein comprises certain 15 sulphydryl compounds and certain zwitterionic surfactants and is described in copending application Serial No. 08/480,632, filed on June 7, 1995 in the name of Donald L. Bissett, incorporated herein by reference. Another desquamation system that is suitable for use herein comprises salicylic acid and certain zwitterionic surfactants and is described in copending patent application Serial No. 08/209,401, filed on March 9, 1994 in the name of Bissett.

**20 K. Depilation Agents**

The compositions of the present invention may include a safe and effective amount of a depilation agent. When used, the composition preferably contains from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2% of depilation agent. A depilation agent preferred for use herein comprises certain sulphydryl 25 compounds, e.g., N-acetyl-L-cysteine. The use of such depilation agents is described in more detail in copending application Serial No. 08/479,878, filed on June 7, 1995, in the name of Greg G. Hillebrand and Vladimir Gartstein, incorporated herein by reference.

**L. Skin Lightening Agents**

The compositions of the present invention may comprise a skin lightening agent. When 30 used, the compositions preferably comprise from about 0.1% to about 10%, more preferably from about 0.2% to about 5%, also preferably from about 0.5% to about 2% of a skin lightening agent. Suitable skin lightening agents include those known in the art. Skin lightening agents suitable for use herein also include those described in copending patent application Serial No. 08/479,935, filed on June 7, 1995 in the name of Hillebrand; and copending patent application Serial No. 08/390,152, filed on February 24, 1995 in the names of Kalla L. Kvalnes, Mitchell A. DeLong, Barton J. 35 Bradbury, Curtis B. Motley, and John D. Carter; both incorporated herein by reference.

**M. Other Combination Actives**

The compositions of the present invention may also include a natural extract of yeast, rice bran or the like such as are known in the art. Such extracts enhance the skin appearance benefits of the present invention, and are preferably used in an amount of from 0.1% to about 20%, more preferably 0.5% to about 10%, also from 1% to about 5%. A natural extract of yeast is preferred

In a preferred embodiment, the compositions of this invention comprise niacinamide, panthenol or a mixture thereof as primary active and a natural extract, preferably a natural extract of yeast.

The compositions preferably comprise an oil absorbent such as are known in the art, e.g. 10 clays (e.g. bentonite), microsponges, and Polytrap.

**Preparation of Compositions**

The compositions of the present invention are generally prepared by conventional methods such as are known in the art of making topical compositions. Such methods typically involve mixing of the ingredients in one or more steps to a relatively uniform state, with or without heating, 15 cooling, application of vacuum, and the like.

**Methods For Regulating the Oily/Shiny Appearance of Skin**

The subject invention relates to methods of regulating the oily and/or shiny appearance of skin. Such methods comprise topically applying to the skin to be treated an effective amount of the compositions of the subject invention so as to deposit an effective amount of primary active on the 20 skin. The term "effective amount", as used herein, means an amount sufficient to regulate the oily and/or shiny appearance of skin as defined herein. In general, a safe and effective amount of the primary actives are left in contact with the skin for a period sufficient to provide noticeable effects, generally after chronic application such as described herein.

The composition can be applied for several days, weeks, months or years at appropriate 25 intervals. The compositions are preferably applied from about four times a day to about once every three days, more preferably from about twice a day to once every other day, also about once a day, until a satisfactory oily and/or shiny skin appearance improvement has been achieved. The regulation of the appearance of oily and/or shiny skin can be observed visually without magnification. Methods of quantifying the regulation of the appearance of oily and/or shiny skin 30 such as are known in the art can also be employed, e.g., sebutape analysis such as known in the art.

Typically, in each application, an effective coating of the skin with primary active is achieved by topically applying (in terms of mg active/cm<sup>2</sup> skin) from about 0.0002 mg/cm<sup>2</sup> to about 35 0.4 mg/cm<sup>2</sup> of primary active to the skin to be treated. More preferably, from about 0.002 mg/cm<sup>2</sup> to about 0.2 mg/cm<sup>2</sup> of primary active is applied. Most preferably, from about 0.02 mg/cm<sup>2</sup> to about 0.1 mg/cm<sup>2</sup> of primary active is applied (the amount of composition that is applied may be, for example, from about 0.01 mg to about 5 mg composition/cm<sup>2</sup> skin, preferably about 1 to about 2 mg composition/cm<sup>2</sup> skin).

The compositions are generally applied by lightly massaging the composition into the skin, typically in the amounts described above.

The compositions of the invention can also be used for regulating oiliness of the scalp and for controlling dandruff. Methods of regulating scalp oiliness and for controlling dandruff are as 5 described above, wherein the composition is applied to the scalp.

Examples

The following examples further describe and demonstrate embodiments within the scope of the subject invention. The examples are given solely for the purpose of illustration and are not to be construed as limitations of the subject invention, as many variations thereof are possible without 10 departing from the spirit and scope of the invention.

Example 1

A water-in-oil topical composition suitable for use as a liquid make-up foundation is prepared from the following ingredients using conventional mixing and formulating techniques such as described below:

Compounding code	Ingredient	Wt. %
A	cyclomethicone	9.25
A	cetyl octanoate	2.00
A	dimethicone copolyol (DC3225C)	20.00
B	talc	3.38
B	pigment	10.51
B	Spheron L-1500	0.50
C	Synthetic Wax Durachem 0602	0.10
C	Arachidyl behenate	0.30
D	cyclomethicone	1.00
D	trihydroxystearin	0.30
E	laureth-7	0.50
E	propyl paraben	0.25
F	fragrance	0.05
G	water	34.44
G	methyl paraben	0.12
G	propylene glycol	8.00
G	niacinamide	4.00
G	glycerin	3.00
G	sodium chloride	2.00
G	sodium dehydroacetate	0.30

Combine the ingredients A and B in a suitable container. Mix the ingredients using a Silverson L4RT mixer equipped w/ a 1" tubular assembly and a square hole screen for 30 minutes at 9000 rpm (the container can be covered to avoid loss of any volatile or other materials). Heat the resultant mixture to 85-90°C. Add ingredients C, mix for 5 minutes at 2100 rpm using a Silverson 5 L4RT mixer equipped w/ a 2" head and a disintegrating screen. The container should be covered to minimize evaporation of cyclomethicone and other volatile or nonvolatile materials. Cool the resultant mixture to 45-55°C.

Combine the ingredients D components and mix until a uniform slurry is formed. Separately, combine the ingredients E and mix until a uniform slurry is formed. Add the resultant 10 slurries to the mixture of A, B and C (which is at 45-55°C), mix for 5 minutes at 2100 rpm using a Silverson L4RT equipped w/ a 2" head and a disintegrating screen. Cool the resultant mixture to 30° C, then add ingredient F. Mix 5 minutes at 2100 rpm using a Silverson L4RT equipped w/ a 2" head and a disintegrating screen.

Combine the ingredients G in a suitable container and mix until all components are 15 dissolved. Slowly add the resultant solution to the mixture of A-F. Emulsify this combination using a Silverson L4RT mixer equipped w/ a 2" head and a disintegrating screen at 2100-5100 rpm (rpms will increase as the mixture thickens), continue mixing for 5 minutes after all of the G mixture is added.

Apply the composition to a person's face once per day in an amount of 1-2 mg 20 composition/cm<sup>2</sup> skin for four weeks, to observe a decrease in facial oil, a reduction in oily breakthrough, longer wear of the foundation, and more even coverage as the time period passes.

Other topical compositions suitable for use as a foundation are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied to the face as described above.

#### 25 Example 2

A topical composition suitable for use as a liquid make-up foundation is prepared from the following ingredients using conventional mixing and formulating techniques.

	wt %
dimethicone copolyol/cyclomethicone (Dow Corning QZ-3225C)	10
cyclomethicone (Dow Corning 344 fluid)	17.74
pigments	3.7
titanium dioxide	8.25
trihydroxy stearin	0.3
aqueous floral extract	0.01
denatured ethanol	4 - 17

salicylic acid	1.45
dipropylene glycol	0 - 14
PVP (polymeric dispersing agent)	1
procectyl AWS (PPG-5 octeth, surfactant)	3
tri-sodium citrate	0.3
tetrasodium EDTA	0.1
glycerin	10 - 30
niacinamide	4
sodium chloride	0.3
water	15.85 - 34.85

Apply the composition to a person's face once per day in an amount of 1-2 mg composition/cm<sup>2</sup> skin for four weeks, to observe a decrease in facial oil and/or shine, a reduction in oily breakthrough, longer wear of the composition, and more even coverage as time passes.

Other topical compositions suitable for use as a foundation are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied to the face as described above.

Example 3

Moisturizers having the compositions A, B or C are prepared from the following ingredients using conventional mixing and formulating techniques.

Ingredient	A	B	C
	wt %	wt %	wt %
Water	68.3	70.3	75.3
niacinamide	5	5	0
Panthenol	1.5	1.5	1.5
acrylates copolymer (DC Polymer powder QS-6603)	2	0	0
Octyl Methoxycinnamate (Parsol MCX)	4	4	4
Glycerin	5	5	5
Propylene Glycol	1.1	1.1	1.1
Isohexadecane (Permethyl 101 A)	2	2	2.00
Tocopheryl Acetate	2	2	2.00
herbal extract in propylene glycol & ethoxydiglycol	1	1	1
Bulylene Glycol	1	1	1
Dimethicone (DC 200 Fluid 1000cs)	1	1	1
Cyclomethicone (DC 344 Silicone Fluid)	1	1	1
Triethanolamine	0.8	0.8	0.8

Cetyl Palmitate (Cutina CP)	0.75	0.75	0.75
Tribehenin (Syncrowax HRC)	0.75	0.75	0.75
Stearoxytrimethylsilane & Stearyl Alcohol (DC 580 Wax)	0.5	0.5	0.5
Phenoxyethanol	0.62	0.62	0.62
Carbomer (Carbopol 954)	0.3	0.3	0.3
Hectorite (Bentone EW)	0.3	0.3	0.3
Acrylates/C10-C30 Alkyl Acrylate Crosspolymer (Pemulen TR 1)	0.2	0.2	0.2
Potassium Cetyl Phosphate (Amphisol K)	0.2	0.2	0.2
Perfume	0.2	0.2	0.2
Disodium EDTA	0.1	0.1	0.1
Xanthan Gum	0.07	0.07	0.07
preservative	0.25	0.25	0.25

Apply the composition to a person's face once per day in an amount of 1-2 mg composition/cm<sup>2</sup> skin for four weeks, to observe a decrease in facial oil and/or shine.

Other compositions are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied to the face as described above.

**Example 4**

A silicone gel containing 2 or 4% niacinamide is prepared from the following ingredients using conventional mixing and formulating techniques.

	wt %
water	89.6-91.6
niacinamide	2 or 4
glycerin	2.08
cyclomethicone (Dow Corning 344 fluid)	1.22
butylene glycol	1
cyclomethicone and dimethiconol (Dow Corning Q2-1401)	0.58
cyclomethicone and dimethicone copolyol (Dow Corning QZ-3225C)	0.58
dimethicone copolyol (Dow Corning 193 polycether)	0.12
acrylates/C10-30 alkylacrylates crosspolymer (Pemulen TR-1)	0.25
carbomer (Carbopol 980)	0.2

DMDM hydantoin and iodopropynyl butyl carbamate (Glydant Plus)	0.2
disodium EDTA	0.1
sodium hydroxide	0.08 - 0.1
	to total 100

Apply the gel to a person's face once per day in an amount of 1-2 ml gel/cm<sup>2</sup> skin for four weeks, to observe a decrease in facial oil and/or shine.

Other silicone gels are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied to the face as described above.

#### Example 5

A liquid shampoo having the composition A, B or C is prepared by combining the following components using conventional mixing and formulating techniques:

	A (w1%)	B (w1%)	C (w1%)
coconut oil	14	18	-
olive oil	3	-	-
castor oil	3	4	-
potassium hydroxide. 85%	4.7	5.3	-
glycerol	2	4	5
ethyl alcohol	4	-	10
sodium hexametaphosphate	1	-	-
perfume	0.3	0.2	q.s
water	64	64	36
borax	-	0.5	-
coconut soap potassium salt	-	-	35
olive oil soft soap	-	-	10
niacinamide	4	4	4

Apply the shampoo to the scalp every other day to once a day to reduce the appearance of oily hair and the occurrence of dandruff. A dose of about 0.5 ml is applied and washed off.

Other liquid shampoos are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied to the scalp as described above.

Example 6

A hair conditioner is prepared by combining the following components using conventional mixing and formulating techniques:

	wt%
PVP K-30 (polymeric dispersing agent)	3
Neobee M-20 (propylene glycol dicaprylate)	5
Dremulsic 1128 (surfactant)	5
water	69.5
triethanolamine	1
carbopol 934 (carbomer, polymeric thickening/dispersing agent)	1
WSP-X250	5
Amerchol L-101(mineral oil/lanolin oil)	3
Lipal 15 CSA	3
preservative	q.s.
perfume	0.5
niacinamide	4

Apply the conditioner to the scalp, preferably to clean hair, every other day to once a day to reduce the appearance of oily hair and the occurrence of dandruff. Apply a dose of about 0.5 ml and wash off.

Other hair conditioners are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied as described above.

Example 7

10 A bath oil having the composition A, B or C is prepared by combining the following components using conventional mixing and formulating techniques:

	A (wt%)	B (wt%)	C (wt%)
POE 20 sorbitan monopalmitate	-	5	22.2
fragrance oil	35	5	4.4
isopropyl myristate	65	-	-
methyl p-hydroxybenzoate	-	0.18	-
propyl p-hydroxybenzoate	-	0.02	-
sodium lauryl sulfate	-	-	10

ninol AA-63	-	-	1
sorbic acid	-	-	0.2
niacinamide	4	4	4
water q.s.	-	100	100

Apply the bath oil to the skin either as prepared or in aqueous diluted form. Apply in a dose of from 1-2 mg oil /cm<sup>2</sup> skin for four weeks, to observe a decrease in skin oil and/or shine. Other bath oils are prepared in the above-described manner using pyridoxine, panthenol or pantothenic acid in place of niacinamide and are applied as described above.

5 While particular embodiments of the subject invention have been described, it will be obvious to those skilled in the art that various changes and modifications to the subject invention can be made without departing from the spirit and scope of the invention. It is intended to cover, in the appended claims, all such modifications that are within the scope of the subject invention.

1. A topical composition for regulating the oily and/or shiny appearance of mammalian skin, characterized in that the composition comprises:
  - (a) a safe and effective amount of an active for regulating the oily and/or shiny appearance of mammalian skin, said active consisting essentially of one or more compounds selected from the group consisting of niacinamide, pyridoxine, panthenol, and pantothenic acid; and
  - (b) a cosmetically acceptable carrier for said active.
2. The composition of Claim 1 wherein said active consists essentially of a mixture of niacinamide and panthenol.
3. The composition of Claim 1 wherein said active consists essentially of niacinamide, preferably substantially pure niacinamide.
4. The composition of Claim 1 comprising 0.01% to 20%, preferably 1% to 5%, more preferably 2.5% to 5%, by weight, of said active.
5. A method of regulating the oily and/or shiny appearance of mammalian skin, characterized by comprising topically applying to the skin of a mammal needing such treatment a safe and effective amount of a topical composition comprising:
  - (a) an active for regulating the oily and/or shiny appearance of the skin, said active consisting essentially of one or more compounds selected from the group consisting of niacinamide, pyridoxine, panthenol, and pantothenic acid; and
  - (b) a cosmetically acceptable carrier for said active.
6. The method of Claim 5 wherein 0.0002 mg to 0.4 mg of said active per cm<sup>2</sup> of skin is topically applied.
7. The method of Claim 5 wherein said active consists essentially of a mixture of niacinamide and panthenol.
8. The method of Claim 5 wherein said active consists essentially of niacinamide, preferably substantially pure niacinamide.
9. The method of Claim 5 wherein the composition comprises 0.01% to 20%, preferably 1% to 5%, more preferably 2.5% to 5%, by weight, of said active.

# INTERNATIONAL SEARCH REPORT

Inte  
nal Application No  
PCT/US 96/17672

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 A61K7/48 A61K7/86

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 095 615 A (S.C. JOHNSON & SON) 7 December 1983 see page 2, line 8 - line 21 see page 3, line 9 - page 7, line 15; claims 1-8; examples 1-18 ---	1,4-6,9
X	STN, File Supplier, Karlsruhe, DE, file XP002026861 Chemical Abstracts, Vol 108, AN=210000 see the abstract & RO 91 889 B (INTreprinderea de PRODUSE COSMETICE "NIVEA") 30 November 1987 ---	1,4-6,9
X	FR 1 588 770 A (TSCHOPP) 16 March 1970 see the whole document ---	1,4-6,9
X	US 5 415 861 A (DUFFY ET AL.) 16 May 1995 see the whole document ---	1,4-6,9
	-/-	

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- 'A' document defining the general state of the art which is not considered to be of particular relevance
- 'E' earlier document but published on or after the international filing date
- 'L' document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- 'O' document referring to an oral disclosure, use, exhibition or other means
- 'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

'&' document member of the same patent family

1

Date of the actual completion of the international search

4 March 1997

Date of mailing of the international search report

17.03.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2200 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax (+ 31-70) 340-3016

Authorized officer

Fischer, J.P.

**INTERNATIONAL SEARCH REPORT**

Int. Appl. No  
PCT/US 96/17672

**C(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 001 079 A (F.HOFFMANN-LA ROCHE) 21 March 1979 see the whole document ---	1,4-6,9
X	DE 14 67 925 A (F.HOFFMANN-LA ROCHE) 16 January 1969 see page 4, line 17 - line 4; claims 1-6; example 2 ---	1,4-6,9
X	FR 2 210 380 A (LANCANT) 12 July 1974 see the whole document ---	1,4-6,9
E	US 5 571 503 A (MAUSNER) 5 November 1996 see the whole document ---	1,4-6,9
X	WO 91 14431 A (LEUNG) 3 October 1991 see the whole document ---	1,4-6,9
X	EP 0 250 300 A (BFB ETUDES ET RECHERCHES EXPERIMENTALES) 23 December 1987 see the whole document ---	1,4-6,9
X	FR 1 351 454 A (SOCIETE D'ETUDES ET DE RECHERCHES PHARMACOTECHNIQUES) 30 December 1963 see the whole document ---	1,4-6,9
X	FR 1 352 978 A (SOCIETE D'ETUDES ET DE RECHERCHES PHARMACEUTIQUES "ERPHAR") 13 January 1964 see the whole document ---	1,4-6,9
X	FR 3 203 M (KLEINWICHS) 22 March 1965 see the whole document ---	1,3-6,8, 9
X	WO 92 19217 A (PROCTER & GAMBLE) 12 November 1992 see the whole document -----	1,4-6,9

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

Int. Appl. No.  
PCT/US 96/17672

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 95615 A	07-12-83	US 4478853 A AU 554864 B AU 1397483 A CA 1201977 A JP 58213705 A US 4970220 A	23-10-84 04-09-86 24-11-83 18-03-86 12-12-83 13-11-90
FR 1588770 A	16-03-70	NONE	
US 5415861 A	16-05-95	US 5472699 A	05-12-95
EP 1079 A	21-03-79	AR 216341 A AU 520842 B AU 3982278 A CA 1113398 A DE 2748463 A FR 2403077 A GB 2004185 A,B JP 1423318 C JP 54049335 A JP 62030162 B NL 7808604 A US 4210654 A	14-12-79 04-03-82 20-03-80 01-12-81 29-03-79 13-04-79 28-03-79 15-02-88 18-04-79 01-07-87 16-03-79 01-07-80
DE 1467925 A	16-01-69	BE 619352 A FR 1326867 A GB 944834 A NL 278987 A OA 928 A SE 303826 B US 3188275 A	22-03-68 09-09-68 08-06-65
FR 2210380 A	12-07-74	NONE	
US 5571503 A	05-11-96	NONE	
WO 9114431 A	03-10-91	AU 654812 B AU 7565891 A CA 2078670 A EP 0527757 A	24-11-94 21-10-91 28-09-91 24-02-93

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International Application No  
**PCT/US 96/17672**

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9114431 A		US 5459153 A		17-10-95
		US 5519039 A		21-05-96
EP 250300 A	23-12-87	FR 2599967 A		18-12-87
		DE 3772464 A		02-10-91
FR 1351454 A	06-05-64	NONE		
FR 1352978 A	29-05-64	NONE		
FR 3203 M		NONE		
WO 9219217 A	12-11-92	AU 2168392 A		21-12-92
		CN 1066384 A		25-11-92